Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on October 4, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 4, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• Maetzold sold 986 shares directly at a price of $28.734.
• Additional sales were made indirectly through various trusts for the benefit of Maetzold's descendants and children.
• These trusts include The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
• The weighted-average sale price for the transactions ranged from $28.300 to $29.005.
• Following the reported transactions, Maetzold directly owns 94,622 shares of common stock.
• Maetzold also indirectly owns shares through several trusts, including 122,866 shares through DJM Grantor Retained Annuity Trust No. 5 and 26,134 shares through DJM Grantor Retained Annuity Trust No. 6.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a routine Form 4 filing, indicating insider trading activity. It's common for executives to sell shares under pre-arranged 10b5-1 plans to avoid accusations of trading on inside information. The market may react slightly negatively to insider selling, but the existence of a 10b5-1 plan often mitigates concerns.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment.

Key Dates